Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR1 | P21554 | 20/20 | 1.00 |
| ▸ | KCNH2 | Q12809 | 19/20 | 1.00 |
| ▸ | CYP1A1 | P04798 | 1/20 | 0.79 |
| ▸ | CYP2C8 | P10632 | 1/20 | 0.79 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.79 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.79 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.79 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3574139 | 0.93 | CNR1 (1.00) | CNR1KCNH2CYP1A1CYP2C8CYP2D6 | |
| SCHEMBL3566537 | 0.89 | CNR1 (1.00) | CNR1KCNH2CYP1A1CYP2C8CYP2D6 | |
| SCHEMBL3570283 | 0.84 | CNR1 (0.82) | CNR1KCNH2CYP1A1CYP2C8CYP2D6 | |
| SCHEMBL3187657 | 0.82 | CNR1 (0.79) | CNR1KCNH2CYP1A1CYP2C8CYP2D6 | |
| SCHEMBL3566442 | 0.82 | CNR1 (1.00) | CNR1KCNH2CYP1A1CYP2C8CYP2D6 | |
| SCHEMBL3517154 | 0.79 | CNR1 (0.74) | CNR1KCNH2CYP1A1CYP2C8CYP2D6 | |
| SCHEMBL29290976 | 0.79 | CNR1 (0.65) | CNR1KCNH2CYP1A1CYP2C8CYP2D6 | |
| SCHEMBL13437706 | 0.75 | CNR1 (0.60) | CNR1KCNH2CYP1A1CYP2C8CYP2D6 | |
| SCHEMBL3177288 | 0.75 | CNR1 (0.80) | CNR1KCNH2CYP1A1CYP2C8CYP2D6 | |
| SCHEMBL3572791 | 0.75 | CNR1 (0.83) | CNR1KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200289458-A1 | TOPICAL FORMULATIONS OF CANNABINOIDS AND USE THEREOF IN THE TREATMENT OF PAIN | INMED PHARMACEUTICALS INC (CA) | 2020-09-17 | — | — | US | claimed |
| US-20190142788-A1 | USE OF TOPICAL FORMULATIONS OF CANNABINOIDS IN THE TREATMENT OF EPIDERMOLYSIS BULLOSA AND RELATED CONNECTIVE TISSUE DISORDERS | INMED PHARMACEUTICALS INC. (CA) | 2019-05-16 | — | — | US | claimed |
| US-7700634-B2 | (Indol-3-yl) heterocycle derivatives as agonists of the cannabinoid CB1 receptor | N.V. ORGANON (NL) | 2010-04-20 | — | — | US | claimed |
| EP-1725232-B1 | (INDOL-3-YL)-HETEROCYCLE DERIVATIVES AS AGONISTS OF THE CANNABINOID CB1 RECEPTOR | ORGANON NV (NL) | 2008-01-23 | — | — | EP | claimed |
| US-12357604-B2 | Topical formulations of cannabinoids and use thereof in the treatment of pain | INMED PHARMACEUTICALS INC. (CA) | 2025-07-15 | — | — | US | disclosed |
| US-12042479-B2 | Use of topical formulations of cannabinoids in the treatment of epidermolysis bullosa and related connective tissue disorders | INMED PHARMACEUTICALS INC. | 2024-07-23 | — | — | US | disclosed |
| US-20200289458-A1 | TOPICAL FORMULATIONS OF CANNABINOIDS AND USE THEREOF IN THE TREATMENT OF PAIN | INMED PHARMACEUTICALS INC (CA) | 2020-09-17 | — | — | US | disclosed |
| US-20190142788-A1 | USE OF TOPICAL FORMULATIONS OF CANNABINOIDS IN THE TREATMENT OF EPIDERMOLYSIS BULLOSA AND RELATED CONNECTIVE TISSUE DISORDERS | INMED PHARMACEUTICALS INC. (CA) | 2019-05-16 | — | — | US | disclosed |
| US-7700634-B2 | (Indol-3-yl) heterocycle derivatives as agonists of the cannabinoid CB1 receptor | N.V. ORGANON (NL) | 2010-04-20 | — | — | US | disclosed |
| US-7700634-B2 | (Indol-3-yl) heterocycle derivatives as agonists of the cannabinoid CB1 receptor | N.V. ORGANON (NL) | 2010-04-20 | — | — | US | disclosed |
| EP-1725232-B1 | (INDOL-3-YL)-HETEROCYCLE DERIVATIVES AS AGONISTS OF THE CANNABINOID CB1 RECEPTOR | ORGANON NV (NL) | 2008-01-23 | — | — | EP | disclosed |
| US-20070142446-A1 | (Indol-3-yl) heterocycle derivatives as a agonists of the cannabinoid cb1 receptor | MERCK SHARP & DOHME B.V. (NL) | 2007-06-21 | — | — | US | disclosed |
| US-20070142446-A1 | (Indol-3-yl) heterocycle derivatives as a agonists of the cannabinoid cb1 receptor | MERCK SHARP & DOHME B.V. (NL) | 2007-06-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070142446-A1 | (Indol-3-yl) heterocycle derivatives as a agonists of the cannabinoid cb1 receptor | CNR1, CNR2, OPRL1 | CNR1 1/4885KCNH2 1011/4885CYP1A1 394/4885 |
| US-12357604-B2 | Topical formulations of cannabinoids and use thereof in the treatment of pain | CNR2, CNR1, LCAT | CNR1 2/4885KCNH2 3256/4885CYP1A1 1301/4885 |
| US-20200289458-A1 | TOPICAL FORMULATIONS OF CANNABINOIDS AND USE THEREOF IN THE TREATMENT OF PAIN | CNR2, CNR1, LCAT | CNR1 2/4885KCNH2 3256/4885CYP1A1 1301/4885 |
| US-12042479-B2 | Use of topical formulations of cannabinoids in the treatment of epidermolysis bullosa and related connective tissue disorders | KRT18, DSP, DSC1 | CNR1 60/4885KCNH2 2662/4885CYP1A1 4129/4885 |
| US-20190142788-A1 | USE OF TOPICAL FORMULATIONS OF CANNABINOIDS IN THE TREATMENT OF EPIDERMOLYSIS BULLOSA AND RELATED CONNECTIVE TISSUE DISORDERS | KRT18, DSP, DSC1 | CNR1 60/4885KCNH2 2662/4885CYP1A1 4129/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.